학술논문
Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis
Document Type
Academic Journal
Author
Source
Journal of Comparative Effectiveness Research. Jan 01, 2016 5(1):39-48
Subject
Language
English
ISSN
2042-6305
Abstract
AIMS:: To analyze administrative claims data from Medicaid, Medicare and commercial insurance sources to estimate stroke risk, bleeding risk, and the use of antithrombotic treatment in patients with atrial fibrillation (AF). METHODS:: Included patients were aged ≥18 years with a new or existing diagnosis of AF. Outcomes were assessed over 1 year and included stroke risk (CHADS2/CHA2DS2-VASc score), bleeding risk (ATRIA score) and anticoagulant use. RESULTS:: A total of 115,906 patients with AF met inclusion criteria between six databases. Among patients with high stroke risk (CHADS2 ≥2) and low bleeding risk (ATRIA 0–3), 42–82% did not receive an antithrombotic. CONCLUSION:: Levels of thromboprophylaxis for high-risk AF patients in real-world data differ significantly from current medical guidelines for stroke prevention.